贝林妥欧单抗治疗复发难治B细胞前体急性淋巴细胞白血病的分子学缓解
该研究评估贝林妥欧单抗治疗的复发难治B细胞前体急性淋巴细胞白血病成人患者中微小残留病(MRD)缓解与结局的关系。90例达完全缓解(CR)或伴部分血液学恢复的CR(CRh)患者中,64例(71.1%)达完全MRD缓解,75例(83.3%)在治疗前2周期内达MRD缓解。达CR/CRh且MRD缓解者的总生存和无复发生存显著长于未达MRD缓解者。
要点
- 复发难治B-ALL经贝林妥欧单抗治疗后,MRD缓解与更长的OS和RFS相关。
- 90例CR/CRh患者中71.1%达完全MRD缓解,83.3%在2周期内达MRD缓解。
- MRD缓解可作为贝林妥欧单抗治疗复发难治B-ALL的预后因素。
核心结论
- 贝林妥欧单抗治疗复发难治B细胞前体ALL中,达MRD缓解与更长的OS和RFS相关,支持MRD缓解作为预后因素。
研究设计与样本
- 评估贝林妥欧单抗治疗的复发难治B细胞前体ALL成人患者中MRD缓解与结局关系的研究,试验注册号NCT01466179。
主要发现
- 90例达CR或CRh患者中,64例(71.1%)达完全MRD缓解,即PCR检测免疫球蛋白/T细胞受体基因重排不可检出(最低灵敏度10^-4)。
- 达CR/CRh且MRD缓解者的中位OS为20.6个月、中位RFS为9.0个月,显著长于未达MRD缓解者的12.5个月和2.3个月。
临床怎么用
- 在贝林妥欧单抗治疗复发难治B细胞前体ALL成人患者中,应评估MRD缓解以判断预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy treatment and is standard of care in treatment monitoring and decision making. Limited data are available on the prognostic value of MRD response after relapse. We evaluated the relationship between MRD response and outcomes in blinatumomab-treated adults with relapsed/refractory (R/R) B-cell precursor ALL. Of 90 patients with complete remission (CR) or CR with partial hematologic recovery (CRh), 64 (71.1%) achieved a complete MRD response (no detectable individual rearrangements of immunoglobulin/T-cell receptor genes by polymerase chain reaction [PCR] at a minimum sensitivity level of 10-4). Eleven patients had MRD <10-4. Therefore, overall, 75 (83.3%) experienced an MRD response (no detectable MRD or detectable MRD) measured by PCR within the first 2 treatment cycles. Overall survival (OS) and relapse-free survival (RFS) were significantly longer in patients who achieved CR/CRh and MRD response (median, 20.6 and 9.0 months, respectively) compared with CR/CRh patients without MRD response (median, 12.5 and 2.3 months, respectively). In conclusion, longer durations of OS and RFS associated with MRD response support the value of achieving MRD response and its use as a prognostic factor for blinatumomab treatment in R/R ALL. This trial was registered at www.clinicaltrials.gov as #NCT01466179.
引用
- Gökbuget N, Kantarjian HM, Brüggemann M, et al. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2019. PMID: 31648325. doi:10.1182/bloodadvances.2019000457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。